Treatment with HHT or venetoclax causes greater apoptosis in OCI-AML2 RUNX1^R174*/wt compared with OCI-AML2 cells. (A) OCI-AML2 and OCI-AML2 RUNX1^R174*/wt cells were treated with the indicated concentrations of HHT for 48 hours. Following this, the percentages of annexin V–positive, apoptotic cells were determined by flow cytometry. Mean of 3 independent experiments + SEM. *P < .05 as determined by a 2-tailed, unpaired t-test. (B-C) Representative immunoblot analysis of OCI-AML2 RUNX1^R174*/wt cells treated with HHT as indicated for 18 hours. (D) OCI-AML5 and Mono-Mac-1 cells were treated with the indicated concentrations of HHT for 48 hours. Following this, the percentages of annexin V–positive, apoptotic cells were determined by flow cytometry. Mean of 3 independent experiments ± SEM. (E) Patient-derived mtRUNX1 and wtRUNX1-expressing AML cells were treated with the indicated concentrations of HHT for 48 hours. The cells were stained with To-Pro-3 iodide and the percentage of nonviable cells was determined by flow cytometry. *P < .05 as determined by a 2-tailed, unpaired t-test utilizing GraphPad V8. (F) OCI-AML2 and OCI-AML2 RUNX1^R174*/wt cells were treated with the indicated concentrations of venetoclax for 48 hours. Following this, the percentages of annexin V–positive, apoptotic cells were determined by flow cytometry. Mean of 4 independent experiments + SEM. *P < .05 as determined by a 2-tailed, unpaired t-test. (G) Representative immunoblot analysis of OCI-AML2 RUNX1^R174*/wt cells treated with venetoclax as indicated for 18 hours.